Keymed Biosciences’ CM336 Shows Promise in Myeloma Study

Keymed Biosciences, Inc. (HK:2162) has released an update.

Keymed Biosciences Inc. has unveiled promising data from its phase I/II clinical study of CM336, a bispecific antibody for treating relapsed or refractory multiple myeloma, at the American Society of Hematology Annual Meeting. The study highlighted CM336’s manageable safety profile and encouraging preliminary efficacy, with significant response rates among patients. This development positions CM336 as a potential novel therapeutic option in the treatment landscape.

For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.